Port-a-cath — Implanted venous access device

A Port-a-cath consists of two main components: a small reservoir (port) made of titanium or medical-grade plastic topped with a self-sealing silicone septum, and a flexible silicone or polyurethane catheter. The port is typically implanted in the subcutaneous tissue of the upper chest wall under local anaesthesia and light sedation. The catheter is threaded into a large central vein, usually the superior vena cava, near the entrance to the right atrium.

Healthcare professionals access the port by inserting a specialised non-coring Huber needle through the intact skin and silicone septum. Because the device sits entirely beneath the skin when not accessed, it eliminates external lines, reducing the risk of catheter-related bloodstream infections. When not in active use, the port is regularly flushed with saline or heparin solution to maintain catheter patency and prevent blood clot formation.

For cancer patients requiring frequent infusions, a port transforms treatment days by eliminating the stress and physical pain of repeated failed cannulations. It provides safe administration of vesicant chemotherapy drugs, which could cause severe tissue damage if they leaked out of peripheral arm veins. Furthermore, having a port-a-cath preserves peripheral veins for the future, reduces hospital delays, and offers a discreet solution that supports psychological well-being, as patients are not constantly reminded of their illness by visible external tubes hanging from their body.

A Port-a-cath is an anatomical access device rather than a biological condition, so it is evaluated through imaging and mechanical tests rather than biomarker assays. Proper catheter placement is verified during or immediately after implantation using fluoroscopy or a post-procedure chest X-ray. During regular clinical use, patency is confirmed by aspirating blood easily and flushing smoothly without resistance. If blockage or thrombosis is suspected, ultrasound or dye-contrast fluoroscopy (portogram) is performed to assess flow.

Port-a-caths are used across nearly all cancer types that require sustained intravenous therapy. They are particularly prevalent in colorectal cancer, where continuous 46- to 48-hour infusions of regimens like FOLFOX or FOLFIRI are standard. Ports are also widely utilized in breast, ovarian, pancreatic, lung, and gastrointestinal cancers, as well as lymphomas and leukaemias requiring long-term chemotherapy, regular blood transfusions, targeted biological therapies, or parenteral nutritional support.

Having a port-a-cath enables the safe, reliable delivery of multi-day continuous systemic chemotherapy via ambulatory infusion pumps carried at home. It also facilitates blood sampling, antiemetic infusions, supportive hydration, and contrast injections for CT imaging (using power-injectable ports). The port remains in place for months or years throughout the treatment course and is removed via a straightforward minor procedure once therapy is successfully completed and remission is stable.